These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1284 related articles for article (PubMed ID: 32622323)
1. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy. Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323 [TBL] [Abstract][Full Text] [Related]
2. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer. Zhang L; Wang XI; Ding J; Sun Q; Zhang S Ann Diagn Pathol; 2019 Jun; 40():143-151. PubMed ID: 31096176 [TBL] [Abstract][Full Text] [Related]
3. A high CD8 to FOXP3 ratio in the tumor stroma and expression of PTEN in tumor cells are associated with improved survival in non-metastatic triple-negative breast carcinoma. Tavares MC; Sampaio CD; Lima GE; Andrade VP; Gonçalves DG; Macedo MP; Cordeiro de Lima VC BMC Cancer; 2021 Aug; 21(1):901. PubMed ID: 34362334 [TBL] [Abstract][Full Text] [Related]
4. Integrative prognostic analysis of tumor-infiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1, and tertiary lymphoid structures in patients with early-stage triple-negative breast cancer who did not receive adjuvant chemotherapy. Yazaki S; Shimoi T; Yoshida M; Sumiyoshi-Okuma H; Arakaki M; Saito A; Kita S; Yamamoto K; Kojima Y; Nishikawa T; Tanioka M; Sudo K; Noguchi E; Murata T; Shiino S; Takayama S; Suto A; Ohe Y; Fujiwara Y; Yonemori K Breast Cancer Res Treat; 2023 Jan; 197(2):287-297. PubMed ID: 36385236 [TBL] [Abstract][Full Text] [Related]
5. Clinicopathological significance of the immunologic signature (PDL1, FOXP3+ Tregs, TILs) in early stage triple-negative breast cancer treated with neoadjuvant chemotherapy. Abdelrahman AE; Rashed HE; MostafaToam ; Omar A; Abdelhamid MI; Matar I Ann Diagn Pathol; 2021 Apr; 51():151676. PubMed ID: 33360026 [TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study. Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640 [TBL] [Abstract][Full Text] [Related]
7. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC). Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168 [TBL] [Abstract][Full Text] [Related]
8. PD-L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy. Chen S; Wang RX; Liu Y; Yang WT; Shao ZM Int J Cancer; 2017 Mar; 140(6):1384-1395. PubMed ID: 27925176 [TBL] [Abstract][Full Text] [Related]
9. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer. Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649 [TBL] [Abstract][Full Text] [Related]
10. Immune characterization of breast cancer metastases: prognostic implications. Dieci MV; Tsvetkova V; Orvieto E; Piacentini F; Ficarra G; Griguolo G; Miglietta F; Giarratano T; Omarini C; Bonaguro S; Cappellesso R; Aliberti C; Vernaci G; Giorgi CA; Faggioni G; Tasca G; Conte P; Guarneri V Breast Cancer Res; 2018 Jun; 20(1):62. PubMed ID: 29929548 [TBL] [Abstract][Full Text] [Related]
11. Combined Evaluation of Tumor-Infiltrating CD8 + and FoxP3 + Lymphocytes Provides Accurate Prognosis in Stage IA Lung Adenocarcinoma. Kinoshita F; Takada K; Yamada Y; Oku Y; Kosai K; Ono Y; Tanaka K; Wakasu S; Oba T; Osoegawa A; Tagawa T; Shimokawa M; Oda Y; Mori M Ann Surg Oncol; 2020 Jun; 27(6):2102-2109. PubMed ID: 31773516 [TBL] [Abstract][Full Text] [Related]
12. Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma. Diana A; Wang LM; D'Costa Z; Allen P; Azad A; Silva MA; Soonawalla Z; Liu S; McKenna WG; Muschel RJ; Fokas E Oncotarget; 2016 Jul; 7(27):40992-41004. PubMed ID: 27329602 [TBL] [Abstract][Full Text] [Related]
13. An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers. Bottai G; Raschioni C; Losurdo A; Di Tommaso L; Tinterri C; Torrisi R; Reis-Filho JS; Roncalli M; Sotiriou C; Santoro A; Mantovani A; Loi S; Santarpia L Breast Cancer Res; 2016 Dec; 18(1):121. PubMed ID: 27912781 [TBL] [Abstract][Full Text] [Related]
14. Expressions of CD8+TILs, PD-L1 and Foxp3+TILs in stage I NSCLC guiding adjuvant chemotherapy decisions. Teng F; Meng X; Wang X; Yuan J; Liu S; Mu D; Zhu H; Kong L; Yu J Oncotarget; 2016 Sep; 7(39):64318-64329. PubMed ID: 27602763 [TBL] [Abstract][Full Text] [Related]
15. PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer. Wang X; Liu Y Pathol Res Pract; 2020 Mar; 216(3):152802. PubMed ID: 32005408 [TBL] [Abstract][Full Text] [Related]
16. The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer. Mori H; Kubo M; Yamaguchi R; Nishimura R; Osako T; Arima N; Okumura Y; Okido M; Yamada M; Kai M; Kishimoto J; Oda Y; Nakamura M Oncotarget; 2017 Feb; 8(9):15584-15592. PubMed ID: 28107186 [TBL] [Abstract][Full Text] [Related]
17. The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome. Arias-Pulido H; Cimino-Mathews A; Chaher N; Qualls C; Joste N; Colpaert C; Marotti JD; Foisey M; Prossnitz ER; Emens LA; Fiering S Breast Cancer Res Treat; 2018 Sep; 171(2):273-282. PubMed ID: 29858752 [TBL] [Abstract][Full Text] [Related]
18. Prognostic Role and Clinical Association of Tumor-Infiltrating Lymphocyte, Programmed Death Ligand-1 Expression with Neutrophil-Lymphocyte Ratio in Locally Advanced Triple-Negative Breast Cancer. Lee J; Kim DM; Lee A Cancer Res Treat; 2019 Apr; 51(2):649-663. PubMed ID: 30064200 [TBL] [Abstract][Full Text] [Related]
19. CD8+/FOXP3+ ratio and PD-L1 expression associated with survival in pT3N0M0 stage esophageal squamous cell cancer. Zhu Y; Li M; Mu D; Kong L; Zhang J; Zhao F; Li Z; Liu X; Bo C; Yu J Oncotarget; 2016 Nov; 7(44):71455-71465. PubMed ID: 27683115 [TBL] [Abstract][Full Text] [Related]
20. Prognostic and clinicopathological significance of PD-L1 and tumor infiltrating lymphocytes in hypopharyngeal squamous cell carcinoma. Hu C; Tian S; Lin L; Zhang J; Ding H Oral Oncol; 2020 Mar; 102():104560. PubMed ID: 31923855 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]